AzurRx (AZRX) Corporate Media Kit

18 MS1819 recombinant lipase for treatment of Exocrine Pancreatic Insufficiency (EPI) • Targeting patients with Cystic Fibrosis (CF) and Chronic Pancreatitis (CP) • Addressing established global market (>$2 billion) (1) Potential synthetic alternative to porcine pancreatic enzyme replacement therapy (PERT) • Clear unmet medical need • Established POC in two therapeutic indications in CF and CP Pursuing parallel monotherapy and combination therapy clinical pathways • Topline Phase 2b CF monotherapy data expected Q1 2021 • Topline Phase 2 CF combination (MS1819 + PERT) therapy data expected Q2 2021 Management Team with combined experience in developing and launching over 25 drugs • Established track record of execution and value creation (1) The CorStar Group 2019. Symphony Health 2019. Investment Highlights Biotechnology company focused on the development of therapeutic proteins for GI indications